Poland· PL-100338807
Berinert 1500
A c1-inhibitor product containing inhibitor c1-esterazy, ludzki, registered in Poland by CSL Behring GmbH.
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Inhibitor C1-esterazy, ludzki
- Manufacturer
- CSL Behring GmbH
- Country
- Poland (PL)
- ATC code
- B02AB03
- ATC class
- C1-Inhibitor
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- gtin059099912130531 fiol.z proszkiem + 1 fiol.z wodą do wstrzykiwań po 3 mlPLN 6921.58
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ce5832ea-77ac-43ab-b1f7-45aa2b93d753 GET /v1/drugs/ce5832ea-77ac-43ab-b1f7-45aa2b93d753?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "1500 j.m./ml",
"packaging": "05909991213053 ¦ Rp ¦ 107359\n1 fiol. proszku ¦ 2 waciki nasączone alkoholem ¦ 1 plaster niejałowy ¦ 1 strzykawka 5 ml ¦ 1 zestaw do wkłucia ¦ 1 fiol. 3 ml rozp. ¦ 1 system do transferu 20/20 z filtrem",
"substance": "Inhibitor C1-esterazy, ludzki 450-625 IU/ml",
"common_name": "Inhibitor C1-esterazy, ludzki",
"pl_product_id": "100338807",
"pozwolenie_nr": "22352",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about c1-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.